Welcome to ALL-SCT BFM International

ALL-SCT BFM international is an open, multicentre, controlled, prospective study for therapy and therapy optimisation in patients with acute lymphoblastic leukaemia (ALL) and an indication for allogeneic hematopoietic stem cell transplantation (HSCT). The target group are children and adolescents less than 18 years old with the diagnosis ALL in first or any following remission with high risk of recurrence of their leukemia.
The main objectives are to evaluate whether HSCT from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD) and to evaluate the efficacy of HSCT from mismatched family or unrelated donors (MMD) as compared to

HSCT from MSD/MD. The standardisation of the treatment options during HSCT from different donor types aims at the optimal comparison of survival after HSCT with survival after chemotherapy only. The incidence of acute and chronic GvHD after HSCT from MSD, from MD and from MMD is evaluated and compared prospectively.
The primary endpoints contain event-free and overall survival after allogeneic HSCT, occurrence of acute and chronic Graft-versus-Host-Disease (GvHD), occurrence and course of late effects after chemotherapy with subsequent allogeneic HSCT.
For further information please click here ...